Kieran is a PhD candidate at the Monash Institute of Pharmaceutical Sciences in Victoria, Australia. His research focuses on using structural biology methods to understand the diverse pharmacology of G protein-coupled receptors, with a particular focus on partial agonists of the cannabinoid receptors, such as THC. Prior to this, he obtained a Masters in Pharmacology from the University of Auckland, New Zealand, investigating the clinical toxicology of rare adverse drug reactions to the antipsychotic drug clozapine. Kieran is deeply interested in all aspects of psychoactive compounds, from fundamental biochemistry to clinical safety.
In the last 10 years, psychiatric interest in the use of psychedelics, such as psilocybin and LSD, has surged. A new study employed mice to examine how LSD could exert changes on the inflammatory response and the gut microbiome.